Oklo and NuScale shares sank 15% in a week as rising bond yields pressured nuclear stocks.

A hot inflation report, not a reactor problem, knocked two of the market's favorite nuclear bets down double digits in a single week.

You'd expect a 15% weekly drop in Oklo and NuScale Power to follow bad reactor news. It didn't. Both stocks fell roughly 15% in the week through Monday, October 19, with Oklo touching a fresh 52-week low, and the trigger sat nowhere near a nuclear plant. It sat in a September inflation report that pushed the 10-year Treasury yield to about 5.3%, the highest level investors had seen since 2007.

That single data point did more damage to Oklo and NuScale than months of permitting delays ever have. The September CPI report showed annual inflation accelerating to 3.7%, above the 3.6% forecast, while core inflation ticked up to 2.6%. Treasury yields jumped roughly 9 to 10 basis points on the news, and the probability traders assigned to another Federal Reserve rate hike this month jumped from around 22% to roughly 50%, according to Trading Economics. For a stock like Oklo, which has no revenue and won't generate meaningful cash for years, a higher discount rate on far-off profits is a direct hit to the valuation math.

The Nasdaq 100 fell too, but nowhere near as hard. The index dropped about 3.7% over the same stretch, a fraction of what hit the two small modular reactor stocks. That gap comes down to what these two companies are now. Oklo and NuScale aren't just tech-adjacent plays on the AI data center buildout anymore; they're long-duration growth bets with none of the cash flow that gives a Microsoft or a Google room to absorb a rate shock. When yields spike, the stocks with earnings furthest in the future get hit first and hardest.

Here's what makes the timing strange. Just days before the stock cratered, Oklo picked up one of the better pieces of news in its young corporate life. On October 13, the Department of Energy selected Oklo's Groves 2 Forge isotope facility for its Nuclear Energy Launch Pad program, part of a push through the Idaho National Laboratory's National Reactor Innovation Center. The Texas facility, located near Lockhart in Caldwell County, is slated to produce lutetium-177, an isotope used in targeted cancer treatment, and builds on Oklo's Groves Isotope Test Reactor, which reached criticality earlier this year.

None of that mattered to the stock. Oklo fell anyway, because a company with a nuclear licensing win and a company with no nuclear news at all were both getting re-priced by the same bond market that weekend. That's the tell. When the thing moving a stock is a macro number rather than anything the company did, the company's own progress stops being the variable that matters, at least for a few weeks.

NuScale's chart tells an even starker version of the same story. The stock hit an all-time high near $57.42 in October 2025 before the broader AI-infrastructure jitters set in, and shares have since fallen to around $9 to $10, a collapse of more than 80% from that peak. Oklo's own round trip has been just as violent: shares that touched an all-time high near $194 in October 2025 had fallen into the $20s and $30s by mid-October 2026, a drop Barclays analysts flagged even as they kept an Overweight rating and a price target implying 117% upside, according to a report cited by TIKR.

So which is it, a bubble popping or a buying opportunity? Frankly, it's both, depending on your time horizon. The AI data center power story that sent these stocks up in the first place hasn't gone away. Hyperscalers are still signing power deals, and the Centrus Energy letter of intent Oklo signed in June, covering enough high-assay low-enriched uranium to fuel up to five of its Aurora powerhouses through 2029 for its planned 1.2 gigawatt Ohio campus, is still on the table. But that deal is a letter of intent, not a signed contract, and Oklo still has zero revenue.

Q3 earnings could change the calculus. Oklo is expected to report in early-to-mid November, with analysts projecting a loss of roughly $0.29 per share for the quarter. Any update on the Centrus supply agreement moving from letter of intent to definitive contract, or new customer terms from a data center operator, would give the stock something to trade on besides Treasury yields. Until then, the market isn't pricing Oklo or NuScale on reactors, isotopes, or megawatts. It's pricing them on where the 10-year goes next.